Get the Stockscreener App
103.80
1.33%
-1.435
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $103.80, with a volume of 2.58M.
It is down -1.33% in the last 24 hours and down -4.41% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$105.23
Open:
$105.18
24h Volume:
2.58M
Relative Volume:
0.24
Market Cap:
$179.56B
Revenue:
$46.59B
Net Income/Loss:
$5.41B
P/E Ratio:
33.55
EPS:
3.0938
Net Cash Flow:
$7.38B
1W Performance:
-4.56%
1M Performance:
-4.41%
6M Performance:
-6.08%
1Y Performance:
-19.74%
1-Day Range:
$103.69
$105.19
1-Week Range:
$103.69
$110.01
52-Week Range:
$81.97
$137.49
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
103.77 | 182.09B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
91.29 | 117.54B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
270.92 | 105.63B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.30 | 65.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.24 | 49.67B | 6.30B | 1.07B | 1.09B | 1.8406 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott Laboratories stock falls after FDA approval - ad-hoc-news.de
Abbott Laboratories Share Price Today (ABT) | Live Chart, News & Stock Market - techgraph.co
Abbott Laboratories stock before the bell falls 2.6 percent - ad-hoc-news.de
Abbott Laboratories (ABT) Secured FDA Approval, Is It Still 11% Below Fair Value? - simplywall.st
Abbott Wins FDA Clearance for Dual-Energy AFib Catheter - finance.biggo.com
Abbott partners with Sengkang General Hospital to advance early detection of muscle loss in Singapore - BioSpectrum Asia
Abbott Is Selling Sterility as a Feature. In Liquid Formula It Is Already the Rule. - marlerblog.com
Abbott Receives FDA Nod for TactiFlex Duo: Stock to Gain? - Yahoo Finance
Abbott garners FDA nod for its TactiFlex catheter to treat AFib - Fierce Biotech
Abbott’s dual ablation catheter lands FDA approval - Yahoo Finance
Abbott Laboratories stock gains after FDA approval and strong guidance - ad-hoc-news.de
Abbott Laboratories stock heads into the open after a modest loss - ad-hoc-news.de
Here's Why Abbott (ABT) Fell More Than Broader Market - Yahoo Finance
Abbott Laboratories stock underperforms Tuesday when compared to competitors - MarketWatch
1 No-Brainer ETF I'm Loading Up on in 2026 and Beyond - The Motley Fool
FDA approves new Abbott catheter capable of PFA and radiofrequency ablation - cardiovascularbusiness.com
Abbott wins FDA approval for dual-energy ablation catheter - MedTech Dive
Abbott receives FDA approval for AFib ablation catheter - grafa.com
Abbott Laboratories (ABT) Won FDA Approval For Its TactiFlex Duo Catheter - simplywall.st
Abbott scores another win at UPC with SiBio preliminary injunction - IAM Patent
Abbott receives FDA approval for dual-energy heart ablation catheter By Investing.com - Investing.com Canada
Abbott wins FDA nod for cardiac ablation catheter (ABT:NYSE) - Seeking Alpha
The FDA Clears an Abbott Product - marketscreener.com
Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms - PR Newswire
Abbott Laboratories stock holds firm after July earnings - AD HOC NEWS
Abbott Laboratories (NYSE:ABT): Can Heart Research Lift Its Next Move? - Kalkine Media
Abbott Blocks Rival's Glucose Monitor Sales In Europe - Law360
Abbott Laboratories stock holds valuation premium amid steady earnings - ad-hoc-news.de
Abbott Laboratories (ABT) Stock Analysis: Analyst Consensus Reveals a 10.96% Upside Potential - DirectorsTalk Interviews
Abbott Stock And Other Defensive Dividend Picks For Uncertain Markets - simplywall.st
Abbott Laboratories stock holds near $108 after strong Q2 - AD HOC NEWS
Abbott Laboratories Profile: Recipients - OpenSecrets
Abbott Laboratories (ABT) Q2 2026 Earnings Call Transcript - Fortune
How New Diabetes, Cardiac, Nutrition and Cancer Tools At Abbott Laboratories (ABT) Have Changed Its Investment Story - simplywall.st
Abbott CFO Philip P. Boudreau Retains 70,784 Shares After Forfeiting 388 Shares at $110.36 Each - Kalkine Media
Ferguson Wellman Capital Management Inc. Sells 136,385 Shares of Abbott Laboratories $ABT - InsuranceNewsNet
Renal Denervation Market Size, Share & Trends Analysis - GlobeNewswire Inc.
US companies face rise in cyber attacks - Reuters
Abbott Laboratories CFO Philip P. Boudreau Reports Sale of 388 Shares at $110.36 in SEC Form 4 Filing - Kalkine Media
Abbott Laboratories VP John A. McCoy Jr. Reports Share Sales on September 1-2, 2026 - Kalkine Media
Abbott Laboratories (ABT) CFO reports small tax-related share disposal - Stock Titan
Abbott Laboratories stock underperforms Thursday when compared to competitors - MarketWatch
Abbott Laboratories stock gains support from fresh earnings and guidance - AD HOC NEWS
Abbott ablation device effective at 1 year in complex cases - MedTech Dive
Small Abbott (NYSE: ABT) insider sale from vested stock award - Stock Titan
Abbott Laboratories stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Abbott settlement and Kendamil case add to formula industry scrutiny - FoodNavigator.com
J.P. Morgan Maintains Abbott Laboratories(ABT.US) With Buy Rating - Moomoo
Abbott Introduces America’s First Liquid Baby Formula With Whole Milk - Yahoo Finance
Abbott Laboratories Stock: Is ABT Underperforming the Healthcare Sector? - Barchart.com
Abbott Laboratories stock underperforms Monday when compared to competitors - MarketWatch
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.58%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):